In phase I/IIa studies for 34 adult patients with atopic dermatitis from moderate to severe (AD), subcutaneously infused high-dose HUC-MSCs (5.0 × 107cells) therapeutically improved the disease features, suggesting the significant reduction of severity scoring and eczema area, severity index for atopic dermatitis, pruritus score, serum IgE levels and the number of blood eosinophils [164]. Here, IGHE is linked to atopic eczema.